CD40LG and bacterial infectious disease: These data show treatment with IgM‐IVIg does not exacerbate brain injury and reduces bacterial infection, and supports future pre‐clinical studies to find a treatment regimen where timing and dosage could be optimized to confers both anti‐infective and brain reparative properties.